Two-year outcome data suggest that less invasive surfactant administration (LISA) is safe. Results from the follow-up of the randomized controlled AMV (avoid mechanical ventilation) study

Eur J Pediatr. 2020 Aug;179(8):1309-1313. doi: 10.1007/s00431-020-03572-0. Epub 2020 Feb 18.

Abstract

Less invasive surfactant administration (LISA) is a method to deliver surfactant to spontaneously breathing premature infants via a thin catheter. Here we report the two-year outcome from the AMV (avoid mechanical ventilation) study, the first randomized controlled trial on this mode of surfactant delivery. No statistically significant differences in weight, length or neurodevelopmental outcome (Bayley II scores) were found between the LISA intervention group (n = 95) and the control group (n = 84) that received standard treatment.Conclusion: No differences in outcome were observed at 2 years. LISA seems safe in that aspect. What is Known: • LISA is a method that is in increasing use for surfactant delivery to spontaneously breathing infants. LISA reduces the need for mechanical ventilation. What is New: • Outcome data at 2 years from the first randomized study with LISA raise no safety concerns in comparison to a group of infants that received standard treatment.

Keywords: LISA – CPAP; Less invasive surfactant; Outcome; Premature infants.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Catheterization
  • Child, Preschool
  • Continuous Positive Airway Pressure
  • Female
  • Follow-Up Studies
  • Growth Disorders / diagnosis
  • Growth Disorders / etiology
  • Growth Disorders / prevention & control*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Neurodevelopmental Disorders / diagnosis
  • Neurodevelopmental Disorders / etiology
  • Neurodevelopmental Disorders / prevention & control*
  • Pulmonary Surfactants / administration & dosage*
  • Pulmonary Surfactants / therapeutic use
  • Respiration, Artificial / statistics & numerical data
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / therapy
  • Treatment Outcome

Substances

  • Pulmonary Surfactants

Supplementary concepts

  • Respiratory Distress Syndrome In Premature Infants

Grants and funding